Magnetic Nanoparticles in Injections: A Scientific Review of Their Function and Risks

Magnetic hyperthermia is a therapeutic procedure that heats tumor cells using magnetic nanoparticles. The mechanism involves: (1) magnetic nanoparticles are absorbed by tumor cells, (2) an alternating external magnetic field causes the nanoparticles to oscillate, (3) this oscillation creates friction between nanoparticles, (4) friction dissipates energy as heat, which destroys the tumor cells. The key principle is that the alternating magnetic field causes the magnetic nanoparticles to rotate and oscillate, generating friction that produces heat. This is analogous to rubbing hands together to generate warmth through friction.

Magnetic hyperthermia therapy (MHT) is an emerging cancer treatment that uses magnetic nanoparticles injected into the bloodstream, which accumulate in tumors and generate localized heat when exposed to an external magnetic field, selectively destroying cancer cells while sparing healthy tissue due to cancer cells' greater sensitivity to heat; this targeted, non-invasive approach offers advantages including precision, reduced side effects, biocompatibility, potential combination with other therapies, and personalized treatment options.

Magnetic nanoparticles are extremely small particles (about 1/1000th the size of a cell) that can be used in cancer treatment by generating localized heat when exposed to an alternating magnetic field; these nanoparticles are injected directly into tumors and, when heated, destroy cancer cells or make them more susceptible to other treatments like chemotherapy or radiation, while coatings on the nanoparticles ensure they reach the correct locations without harming healthy cells or clumping together.

Magnetic hyperthermia is an emerging cancer treatment that uses magnetic nanoparticles (typically ferrite or magnetite-based) to selectively destroy cancer cells by generating heat when exposed to an alternating magnetic field; the nanoparticles accumulate specifically at tumor sites through targeting mechanisms, and they produce heat through two primary mechanisms—hysteresis loss in larger multi-domain particles and relaxation losses (Néel and Brownian relaxation) in smaller single-domain particles—thereby inducing tumor cell death through elevated temperatures (39-45°C) that increase oxidative stress and disrupt cellular processes without causing widespread damage to healthy tissue.

Magnetic hyperthermia uses iron oxide nanoparticles (15 nm) to destroy tumors. When injected and exposed to external magnetic fields, nanoparticles vibrate at 100,000 times per second, generating heat that raises tumor temperatures to 43°C, killing cancer cells while sparing healthy tissue. Nanoparticles are essential because larger particles require impractically high doses (1g/gram of tumor) and cannot target tumors precisely. Surface coatings enable nanoparticles to remain localized within tumors rather than migrating into healthy tissue.

This section connects lysosomal damage to systemic inflammatory responses. Lysosomal rupture triggers NLRP3 inflammasome activation, processing pro-IL-1β into mature IL-1β and activating caspase-1. Caspase-1 cleavage of gasdermin D creates membrane pores inducing pyroptosis—a form of inflammatory cell death. Knockout studies confirmed NLRP3 and ASC dependency. This pathway links nanoparticle exposure to chronic inflammation and tissue injury through well-characterized molecular cascades.

Nanoparticles induce inflammation through a cascade of molecular events. Their large surface area enables generation of reactive oxygen species (ROS), which deplete cellular antioxidants like glutathione. ROS activate calcium signaling pathways in macrophages, triggering nuclear translocation of transcription factors such as NF-κB. This activates genes producing pro-inflammatory cytokines that recruit additional immune cells. Unlike high-dose exposures that kill cells, low-dose nanoparticle exposure activates cells, creating sustained inflammatory responses that can worsen pre-existing conditions like asthma, cardiovascular disease, or diabetes.

Nanotoxicology research has achieved remarkable progress by bringing together scientists, regulators, policy makers, and funding stakeholders. The community began without shared language or vision but has achieved remarkable convergence. However, concerns exist about the field's status, and there is a need to establish credentials more clearly. Nanoparticle interactions with cells are fundamentally different from small molecules - nanoparticles are trafficked to lysosomes within 30 minutes and show active biological transport, while small molecules distribute conventionally. Nanoparticle interactions with cells depend on their context in quite a different way than small molecules. Nanoparticles are covered by biomolecules absorbed from the environment, and their interaction with cells is largely a consequence of what is absorbed, not just size or shape. The dispersion medium chosen significantly affects outcomes - 10% serum from cows with human cells makes a specific choice that may not be appropriate. Nanoparticles dispersed in human plasma show size shifts due to absorbed proteins. The amount of nanoparticles taken into cells is very dependent on the protein environment. In the absence of serum, silica nanoparticles cause cell death, but with sufficient serum, conventional biological processes are restored. Nanoparticles with high surface energy can damage cell surfaces when not properly coated with biological media. Nanoparticles undergo charge reversal when in the presence of proteins, with zeta potential showing overcompensation and the sign of charge actually reversing. In nanotoxicology experiments, 10% serum is added to feed cells, and Fetal Calf Serum is used because it is cheap, but this practice may be dangerous without critical evaluation. The choice of medium should match the biological target - human cells should use human serum, not FCS. In practice, nanoparticles could never present themselves to organisms unless fully covered by biological media. Most damage scenarios observed in vitro may not be realistic. Positive controls for apoptosis in nanotoxicology are affected by serum amount - proteins are carried into cells and particles act like Trojan horses reaching new places in the cell where they induce damage through distinctive signaling cascades. This produces a very different mode of action compared to chemical controls. The categories of nanoparticle-induced apoptosis are quite small compared to the broader range of apoptotic mechanisms seen with chemicals. Each new nanoparticle-induced mechanism found requires another positive control, but nanoparticles tend to act in a narrower range of mechanisms, making it possible to develop appropriate positive controls for specific nanoparticle-induced processes.

Nanoparticle toxicity involves multiple mechanisms: direct membrane interaction causing thinning and pore formation; mitochondrial dysfunction disrupting electron transport chains; oxidative stress as a universal mechanism producing reactive oxygen species causing lipid peroxidation, protein oxidation, and DNA damage; activation of cell signaling pathways (MAPK, p-53) leading to inflammation and apoptosis; ion homeostasis disruption; metal ion release from internalized nanoparticles; lysosomal damage; frustrated phagocytosis; and nuclear entry (particles <14 nm) causing DNA damage. Nanoparticles are classified by geometry (dots, wires, sheets) and chemistry (metals, ceramics, carbons, polymers). Metal nanoparticles provide antimicrobial properties; ceramics are used in sunscreen; carbons for electronics; polymers for medicine. Regulatory oversight is emerging with OECD and national agency guidelines. Challenges include rapidly evolving nanomaterials, limited epidemiological data, and need for precautionary regulation.

Nanotoxicology studies the toxicity of nanomaterials, addressing the fundamental challenge of balancing beneficial biomedical applications against potential harmful effects. When designing nanoparticles for medical use, researchers must determine acceptable toxicity levels—enough to achieve therapeutic effects while minimizing harm to healthy tissues. Nanotoxicity can manifest at any biological scale, from molecular interactions with DNA and proteins to organismal effects including neurological diseases (Parkinson's, Alzheimer's), respiratory conditions, and cardiovascular problems. Nanoparticle toxicity operates through multiple mechanisms: reactive oxygen species (ROS) generation damages DNA, proteins, and cell membranes; protein corona formation alters properties when nanoparticles enter biological fluids; macrophage overload compromises immune function; and physical damage occurs when nanoparticles puncture cell membranes due to their small size relative to membrane thickness (2-3 nanometers). Nanoparticle distribution depends on size and composition: small particles (5nm) are filtered by kidneys, medium particles may be metabolized by the liver, and larger particles accumulate in spleen and liver. Key properties affecting toxicity include size (1-100nm, overlapping with proteins and viruses), form (spheres, cubes, rods, complex polyhedra), composition (metals, metal oxides, polymers, lipids), and surface functionalization (antibodies, polymers, markers). Surface charge is critical because cell membranes are negatively charged, making positively charged nanoparticles more readily taken up by cells. Size is particularly important because smaller particles have proportionally larger surface areas, allowing more ion release and reactive oxygen species generation per unit mass.

The FDA regulates nanomedicine products using a unified risk-based approach that applies the same safety, efficacy, and quality standards as conventional products, with key considerations including nanomaterial characterization (particle size, shape, charge, surface coating, stability), technology maturity, and the relationship between nanomaterial attributes and product performance; the agency encourages early and ongoing communication with innovators to navigate the complex regulatory landscape effectively.

Toxicology is a branch of pharmacy studying chemical substance effects on living organisms, focusing on human exposure to substances whether intentional or unintentional. It has evolved alongside medicine, developing evaluation methods that now serve as critical regulatory tools. Toxicology is considered the 'fifth power' in science, holding authority in establishing exposure limits. The fundamental principle is that risk equals danger multiplied by exposure. Different standards apply to workers versus general populations. In medicine, an accepted doctrine holds that drug side effects are acceptable collateral damage. Nanomedicine, developed in the 1990s, uses nanoparticles to deliver drugs but has never been properly evaluated for safety, lacking adequate toxicological tools.

The FDA regulates nanomedicines under existing frameworks without separate nanotechnology-specific regulations. Regulatory decisions are based on three fundamental product attributes: quality, safety, and efficacy. The FDA considers nanotechnology as materials in the 1-100 nanometer range exhibiting unique phenomena enabling novel applications, with the definition extending beyond 100 nanometers up to a micron size if unique properties are present. FDA requires comprehensive characterization including identity, strength, quality, purity, potency, bioavailability, stability, manufacturing process, controls, and analytical procedures. Unlike small molecule drugs characterized by NMR, HPLC, and mass spectrometry, nanomedicines require additional techniques such as electron microscopy, dynamic light scattering, and static light scattering. Nanomedicines often contain surface coatings that significantly influence biological behavior, affecting pharmacokinetics, biodistribution, safety, and efficacy. Beyond size and coating, nanoparticle charge and shape significantly affect biological behavior. FDA has approved nanomedicines for over 40 years, with Doxil (doxorubicin encapsulated liposome) approved in 1995 as an early example. FDA submissions typically enter through IND (Investigational New Drug) applications for new drugs or IDE (Investigational Device Exemption) for devices. Nanomedicine preclinical development requires comprehensive physical-chemical characterization of nanoparticles including drug-loaded formulations. GMP-compliant nanomedicines require sterilization while maintaining product integrity. Gamma radiation can completely change metal nanoparticle structure, while steam sterilization is unsuitable for biologics. Interactions between nanoparticles, biologics, and storage/delivery vessels cause protein aggregation. Endotoxin measurement is a critical challenge for nanomedicines, where standard testing techniques face interference issues. EU clinical trials require facing national regulatory agencies for each country. The new EU Medical Device Regulation (MDR) creates significant challenges for nanomedicines, with many devices facing higher classification requiring more extensive clinical evidence and lifecycle updates. Individual device traceability is required rather than batch-level, increasing manufacturing costs.

Regulatory authorities worldwide face significant challenges in developing harmonized frameworks for nanomedicine approval due to the unique properties of nanomaterials, requiring early engagement with developers, flexible assessment approaches, and international collaboration to balance innovation acceleration with patient safety.

Successful nanomedicine development requires rigorous translational thinking. Researchers must ask if their nanoparticles can achieve regulatory approval and whether they would trust their own findings on loved ones. NIH and FDA promote in vitro organoid models to reduce animal testing, enabling high-throughput screening compatible with AI and big data. These 3D cell culture systems provide clinically relevant validation before animal studies, accelerating the path toward clinical translation while minimizing ethical concerns about animal use.